-45%

est. 2Y upside i

HealthcareSeries D+

Rank

#2444

Sector

Biotechnology

Est. Liquidity

~3Y

Data Quality

Data: Medium

Ossium Health presents a moderate upside opportunity driven by its strong proprietary platform addressing critical unmet needs in stem cell transplantation.

Last updated: March 10, 2026

Bull (25%)+200%

Successful Phase 2/3 clinical trials for HPC, Marrow and CHIMERA lead to accelerated FDA approvals, establishing Ossium as a leader in off-the-shelf stem cell therapies. This drives significant market penetration and an acquisition by a large pharma company or a successful IPO at a valuation of $500M-$1B, representing a 2x-4x return.

Base (40%)+30%

Continued positive, but slower, clinical progress for HPC, Marrow, securing initial regulatory approvals for niche indications. Ossium maintains its unique market position but faces ongoing capital needs and moderate competition, leading to an exit (IPO or acquisition) at a valuation of approximately $245M-$300M, a modest upside for common shareholders.

Bear (35%)-70%

Clinical trial setbacks, unexpected safety concerns, or significant delays in regulatory approval for key products. The high capital intensity requires further funding rounds at a flat or lower valuation, and with $126M in liquidation preferences, common stock value is significantly impaired or wiped out in an exit below $189M, potentially leading to a valuation of $50M-$75M.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

67%

Investors hold $126M in liquidation preferences ahead of common stock, meaning a significant portion of any exit value below $189M would go to preferred shareholders first.

Dilution Risk

high

As a clinical-stage biotech with very high capital intensity, further substantial funding rounds are highly probable before commercialization, leading to additional dilution for existing equity holders.

Secondary Liquidity

none

There is no public information indicating active secondary markets or tender offers for Ossium Health's employee equity.

Other — 13 roles

View all 13 open roles at Ossium Health →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Ossium Health's data — designed to show you've done your homework.

  • 1

    “How is Ossium Health planning to integrate its deceased donor bone marrow platform with existing transplant infrastructure, such as Be The Match, while maintaining its competitive differentiation?”

  • 2

    “What are the key clinical and regulatory milestones anticipated for the PRESERVE I study and other pipeline products (CHIMERA, CHYMALIS) in the next 12-24 months, and what are the biggest anticipated hurdles?”

  • 3

    “Given the significant capital raised ($126M) and the current Series D valuation ($189M), what is the company's strategy for managing potential future dilution, and what is the realistic timeline for a liquidity event for common shareholders?”

Community

Valuation Sentiment

Our model estimates -45% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.